Cocrystal Pharma, Inc. (COCP) Dividend History

Company News

• Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

  Cocrystal Pharma is extending enrollment in a Phase 2a study of its influenza antiviral candidate CC-42344 due to unexpectedly low influenza infection rates among study participants. The drug showed a favorable safety and tolerability profile, but the low infection rates hindered the analysis of its antiviral activity.

  GlobeNewswire Inc.
• Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?

  When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

  Zacks Investment Research
• Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

  BOTHELL, Wash., May 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

  GlobeNewswire Inc.
• Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

  BOTHELL, Wash., March 28, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

  GlobeNewswire Inc.
• Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

  Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial

  GlobeNewswire Inc.